Asceneuron

Asceneuron is a clinical-stage biotech company developing small molecule therapies that target tau protein aggregation in neurodegenerative diseases. Its pipeline includes oral OGA inhibitors for conditions such as progressive supranuclear palsy and Alzheimer’s disease, with additional programs in earlier stages.

Asceneuron aims to address the underlying biology of these disorders to improve patient outcomes.